Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ERC 124

Next Previous
Drug Profile

ERC 124

Alternative Names: Endometrial blood stem cell therapy - Intrexon; Endometrial regenerative cells; ERC-124

Latest Information Update: 07 Feb 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MediStem Laboratories; Yale University
  • Developer Brigham and Womens Hospital; ERCell LLC; Intrexon Corporation; Yale University
  • Class Heart failure therapies; Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Brain injuries; Chronic limb-threatening ischemia; Heart failure; Peripheral vascular disorders; Type 1 diabetes mellitus

Most Recent Events

  • 03 Feb 2020 Intrexon Corporation is now called Precigen Inc
  • 03 Oct 2015 No recent reports of development identified - Clinical-Phase-Unknown for Chronic limb threatening ischemia in China (IM)
  • 03 Oct 2015 No recent reports of development identified - Phase-II for Heart failure in Russia (Intracoronary)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top